Fortrea divests Endpoint Clinical & Patient Access businesses to Arsenal Capital Partners.

Fortrea completes divestiture of Endpoint Clinical & Patient Access businesses to Arsenal Capital Partners, a private equity firm specializing in healthcare & industrial growth companies. Endpoint provides RTSM, while FPA focuses on patient access solutions, both offering distinct entry points within pharmaceutical services. Fortrea, a global CRO, retains its core operations.